President Donald Trump signed an executive order on Saturday aimed at accelerating research and potential therapeutic access to psychedelic drugs like ibogaine and psilocybin, marking a rare policy shift from an administration typically cautious about drug liberalization. The move, announced in the Oval Office with Health Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and former Navy SEAL Marcus Luttrell present, seeks to fast-track federal review of substances long stigmatized but increasingly embraced by veterans and advocacy groups for treating PTSD and addiction.
Trump framed the initiative as a potential breakthrough for millions suffering from debilitating conditions, echoing sentiments shared across the political aisle. “If these turn out to be as fine as people are saying, it’s going to have a tremendous impact on this country and other countries, too,” he said, noting that federal regulators had already designated some psychedelics as potential breakthrough therapies. The order directs the administration to speed up reviews and ease access to research, though it does not reclassify ibogaine or psilocybin from their current Schedule I status under federal law, which labels them as having no accepted medical use and a high potential for abuse.
The focus on ibogaine, a psychoactive compound derived from a West African shrub, has drawn particular attention due to its use in unregulated clinics abroad — often in Mexico or the Caribbean — by Americans seeking treatment for opioid dependence and trauma. CBS News reported that the executive order is intended to open the door to federal funding for research into ibogaine’s effectiveness for PTSD and traumatic brain injuries, especially among veterans, a population disproportionately affected by both conditions. Texas has already committed $50 million to ibogaine research under Governor Greg Abbott, signaling growing state-level interest despite federal restrictions.
Supporters within the veteran community have been vocal about ibogaine’s purported benefits. Marcus Luttrell told Trump during the signing ceremony that the drug “absolutely changed my life for the better,” while Joe Rogan revealed he had personally texted the president information about ibogaine, to which Trump responded: “Sounds great. Do you desire FDA approval? Let’s do it.” These personal endorsements underscore a growing grassroots push that has found unexpected alignment with certain conservative lawmakers and veterans’ organizations, creating a rare bipartisan opening in drug policy discourse.
For more on this story, see Donald Trump 2024 Endorsements: Notable Government Officials.
Yet the enthusiasm is tempered by significant safety concerns. Ibogaine is known to cause dangerous heart rhythm disturbances, including potentially fatal cardiovascular toxicity. The National Institutes of Health halted research on the drug in the 1990s due to these risks, and a 2023 review of 24 studies involving 705 people concluded that while ibogaine may reduce withdrawal symptoms and cravings, its cardiac toxicity and mortality risk remain “worrying.” At least 27 deaths have been linked to ibogaine use, according to that analysis. Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, noted that “it’s been incredibly difficult to study ibogaine in the U.S. Because of its known cardiotoxicity,” highlighting the scientific hurdles ahead.
The FDA is set to issue national priority vouchers next week for three psychedelics — a first for the agency — which could expedite approval if the drugs align with national health priorities. FDA Commissioner Marty Makary said the vouchers would allow certain compounds to be approved quickly under fast-track mechanisms. The agency is preparing to clear the way for the first-ever human trials of ibogaine in the United States, a step long blocked by regulatory and safety barriers.
Researchers caution that current evidence remains limited. Most data come from small observational studies and open-label trials, with only one double-blind, placebo-controlled randomized clinical trial completed to date. More advanced trials are just beginning, meaning any conclusions about efficacy or safety are premature. As one Trump official put it, the administration wants to determine whether ibogaine is “snake oil” or a legitimate treatment — a question that will require rigorous, large-scale study to answer.
The executive order reflects a broader, quiet shift in how psychedelics are viewed in American medicine and policy. Once confined to countercultural fringes, substances like psilocybin and ibogaine are now being examined in mainstream medical settings, driven by veteran advocacy, state-level experimentation, and growing public interest in alternative mental health treatments. What remains unresolved is how the federal government will balance the promise of these drugs with their demonstrable risks — a tension that will play out in laboratories, clinics, and regulatory agencies over the coming years.
Will this executive order craft psychedelics like ibogaine legal for medical use?
No. The Trump administration has explicitly stated it does not plan to reclassify ibogaine or other psychedelics from Schedule I status at this time, meaning they remain illegal under federal law outside of approved research settings.
Why is ibogaine considered particularly risky compared to other psychedelics?
Ibogaine carries a known risk of causing dangerous heart rhythm disturbances, including ventricular tachycardia, which can be fatal. This cardiovascular toxicity has led to at least 27 documented deaths and caused the NIH to discontinue research in the 1990s.
What role are veterans playing in pushing for psychedelic research?
Veteran organizations and individuals like Marcus Luttrell have advocated for ibogaine and similar substances, citing personal success in treating PTSD and opioid addiction, and have helped drive both state-level funding (such as Texas’s $50 million initiative) and federal interest in further study.
